Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness of Yangxue Qingnao Granules in Preventing Post Thrombolytic Hemorrhage Transformation in Patients With Acute Cerebral Infarction: a Randomized Controlled Study

NCT06344312 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.

NCT NCT06344312
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06344312 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness of Yangxue Qingnao Granules in Preventing Post Thrombolytic Hemorrhage Transformation in Patients With Acute Cerebral Infarction: a Randomized Controlled Study
Lead sponsor
Peking University Third Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
January 1, 2024
Completion date
June 1, 2025
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stroke, acute ischemic